Article
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML.
Leukemia - 1 Jun 2025
Ikoma Yoshikazu, Nakamura Nobuhiko, Kaneda Yuto, Takamori Hiroyuki, Seki Tomokazu, Hiramoto Nobuhiro, Kitagawa Junichi, Kanda Junya, Fujita Kei, Morishita Tetsuji, Ochi Yotaro, Chiba Shigeru, Sasaki Nana, Ichii Michiko, Imada Kazunori, Watanabe Mizuki, Hishizawa Masakatsu, Miyahara Yasuko, Maesako Yoshitomo, Tanaka Yasuhiro, Oka Satoko, Tsuji Masaaki, Yoshihara Satoshi, Mitani Kinuko, Ueda Yasunori, Kitano Toshiyuki, Watanabe Mitsumasa, Sezaki Nobuo, Kondo Tadakazu, Kasahara Senji, Takaori-Kondo Akifumi, Kanemura Nobuhiro, Ogawa Seishi, Nannya Yasuhito
Abstract excerpt
Venetoclax plus azacitidine (VEN + AZA) is widely used in acute myeloid leukemia (AML). This study explored the role of static and dynamic profiles of mutational clonal burden to predict outcomes by analyzing marrow samples from 228 VEN + AZA treated AML cases at "Pre-treatment" (n = 228), "Best-response" (n = 105), and "Relapse" (n = 27) phases using targeted-capture sequencing. In a multivariate model, older...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.